Is Infinity Pharmaceuticals Inc. Stock Good For Long-Term Investing?

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) traded at $1.47 at last check on Monday, January 10, made a downward move of -2.48% on its previous day’s price.

Looking at the stock we see that its previous close was $1.51 and the beta (5Y monthly) reads 1.96 with the day’s price range being $1.475 – $1.70. In terms of its 52-week price range, INFI has a high of $5.98 and a low of $1.48. The company’s stock has lost about -36.55% over that past 30 days.


3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Infinity Pharmaceuticals Inc. has a market cap of $140.60 million and is expected to release its quarterly earnings report on Mar 14, 2022 – Mar 18, 2022. Estimates by analysts give the company expected earnings per share (EPS) of -$0.13, with the EPS growth for the year raised at -$0.53 for 2021 and -$0.58 for next year. These figures represent 22.10% and -9.40% growth in EPS for the two years respectively.

The median projection represents growth adding up to -33.50% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $1.72 million, or 0.10% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the INFI stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Looking further, we note the current price level is -36.60% off its SMA20 and -37.34% from its 50-day simple moving average. The RSI (14) is pointing at 28.04 while the volatility over the past week is 14.79% and jumps to 9.76% over the past one month. The beta value is 1.99, while the average true range (ATR) is currently pointing at 0.22.

Let’s briefly compare Infinity Pharmaceuticals Inc. (INFI) stock to its peers. We find that today’s price change of -2.48% and -38.37% over the past 12 months for INFI competes that of AbbVie Inc. (ABBV), which has seen its stock price rise 0.34% in the latest trading session and is 25.74% over the last one year. Another of its peers Madrigal Pharmaceuticals Inc. (MDGL) has gained 5.29% today, and was -33.17% down over the past year, while Bristol-Myers Squibb Company (BMY) is also up 2.67% yet, while its price remains in the green at 0.54% over the same period. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -2.01% and -1.63%, respectively, in early deals.

Coming back to Infinity Pharmaceuticals Inc. (NASDAQ:INFI), we note that the average 3-month trading volume was 1.67 million. Current shares outstanding are 88.77 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

The insiders hold 2.17% of the company’s shares while institutions hold 58.70%. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -32.89% down in year-to-date price movement.